AstraZeneca and Ionis Pharma have an EU green light for their Wainzua therapy for hereditary transthyretin-mediated amyloidosis (ATTR) polyneuropathy, building on earlier approvals in the US and UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results